Citations

Clear

1134 citation(s) found for "Yan, Su".

Diagnosis, symptoms, and treatment knowledge of aberrant right subclavian artery in followers of a social media group
Olson, Caroline G. , Valery, Jose R. , Bi, Yan , Pocchetino, Alberto, Olson, Caroline , Cortés, Pedro , Stancampiano, Fernando F. , Harris, Dana M.

Mayo Clinic

Romanian Journal of Internal Medicine | October 21, 2022 | Volume: 61 | Issue: 1 | Pages: 3-5

10.2478/rjim-2022-0019 | PMID 36278963 Get It

A phenotype-based forward genetic screen identifies Dnajb6 as a sick sinus syndrome gene
Ding, Yonghe , Yan, Jianhua , Li, Hongsong , Jiao, Kunli , Yang, Jingchun , Port, Jenna , Wang, Jun , Shi, Yongyong , Li, Yi‐Gang , Bu, Haisong, Clark, Karl J , Ekker, Stephen C , Lin, Xueying , Ding, Yonghe , Lang, Di , Bu, Haisong , Ni, Haibo , Morotti, Stefano , Le, Tai , Clark, Karl J. , Ekker, Stephen C. , Cao, Hung , Zhang, Yuji , Grandi, Eleonora , Li, Zhiqiang , Glukhov, Alexey V. , Xu, Xiaolei

Mayo Clinic

eLife | October 18, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.77327 | PMID 36255053 Get It

Previously we showed the generation of a protein trap library made with the gene-break transposon (GBT) in zebrafish ( Danio rerio ) that could be used to facilitate novel functional genome annotation towards understanding molecular underpinnings of human diseases (Ichino et al, 2020). Here, we report a significant application of this library for discovering essential genes for heart rhythm disorders such as sick sinus syndrome (SSS). SSS is a group of heart rhythm disorders caused by malfunction of the sinus node, the heart’s primary pacemaker. Partially owing to its aging-associated phenotypic manifestation and low expressivity, molecular mechanisms of SSS remain difficult to decipher. From 609 GBT lines screened, we generated a collection of 35 zebrafish insertional cardiac (ZIC) mutants in which each mutant traps a gene with cardiac expression. We further employed electrocardiographic measurements to screen these 35 ZIC lines and identified three GBT mutants with SSS-like phenotypes. More detailed functional studies on one of the arrhythmogenic mutants, GBT411 , in both zebrafish and mouse models unveiled Dnajb6 as a novel SSS causative gene with a unique expression pattern within the subpopulation of sinus node pacemaker cells that partially overlaps with the expression of hyperpolarization activated cyclic nucleotide gated channel 4 (HCN4), supporting heterogeneity of the cardiac pacemaker cells.
Outcomes of Malignancy in Adults with Congenital Heart Disease: A Single Center Experience
Venkatesh, Prashanth , Yan, Kimberly , Lluri, Gentian , Bravo‐Jaimes, Katia , Yang, Eric H.

Mayo Clinic

No container title available | September 30, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2109843/v1 Get It

Abstract Background Malignancy is known to be a major cause of death in adult congenital heart disease (ACHD). However, data regarding cardiovascular and cancer-related outcomes in ACHD are lacking. Methods We conducted a retrospective single-center cohort study comprising patients with ACHD and malignancy. The primary outcome was all-cause mortality. Key Secondary outcomes included major adverse cardiovascular and cerebrovascular events (MACCE), cardiotoxicity events and consequent cancer therapy modifications. Results Sixty-eight patients with ACHD and a history of cancer were included in the study. 82% of patients had moderate or great ACHD anatomic complexity. Over a median follow-up of 5 years after cancer diagnosis, 16 (24%) patients died, with 69% of deaths being due to cancer. Univariate predictors of mortality were baseline arrhythmia (OR 3.82, 95% CI 1.15-12.67, p = 0.028), baseline diuretic therapy (OR 3.54, 95% CI 1.04-12.04, p = 0.044) and advanced cancer stage at diagnosis (OR 2.37, 95% CI 1.32-4.25, p = 0.004). MACCE occurred in 40 (59%) patients and was independently predicted by baseline diuretic requirement (OR 9.91, 95% CI 1.12 - 87.85, p = 0.039). A14% incidence of cardiotoxicity was seen; 3 patients needed modification and 1 patient needed temporary interruption of cancer therapy for 2 weeks. Conclusions Considerable mortality occurred in this cohort of patients with ACHD and cancer; most deaths were cancer-related. A high rate of MACCE was observed, yet rates of obligatory modification of cancer therapy due to cardiotoxicity were low.
Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease
Joseph‐Mathurin, Nelly , Li, Yan , McCullough, Austin , Hofmann, Carsten, Wojtowicz, Jakub , Park, Ethan, Wang, Guoqiao , Preboske, Gregory M., Gordon, Brian A. , Chen, Charles D., Flores, Shaney , Aggarwal, Neelum T. , Berman, Sarah , Bird, Thomas D., Borowski, Bret, Chhatwal, Jasmeer P. , Clarnette, Roger, Fagan, Anne M. , Farlow, Martin R. , Fox, Nick C. , Gauthier, Serge , Hassenstab, Jason , Hobbs, Diana A. , Holdridge, Karen C. , Hornbeck, Russ C. , Jiménez‐Velázquez, Ivonne Z. , Klein, Gregory , Xiong, Chengjie , Mancini, Michele , McKay, Nicole S. , Mummery, Catherine J. , Ringman, John M. , Snider, B. Joy, Suzuki, Kazushi , Yaari, R. , Perrin, Richard J. , Bateman, Randall J. , Salloway, Stephen , Clifford, David B., Unit, For the Dominantly Inherited Alzheimer Network Trials, Wang, Qing , Gordon, Brian A , Chen, Charles D , Jucker, Mathias , Ringman, John M , Salloway, Steve , Benzinger, Tammie L S , Bateman, Randall J , Joseph-Mathurin, Nelly , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Berman, Sarah , Llibre‐Guerra, Jorge J. , Li, Yan, Wáng, Qīng , Black, Sandra E. , Brooks, William S. , Cruchaga, Carlos , Honig, Lawrence S. , Hsiung, Ging‐Yuek Robin , Jack, Clifford R. , Masellis, Mario , Shimada, Hiroyuki , Wallon, David , Xiong, Chengjie , McDade, Eric , Benzinger, Tammie L.S. , Unit, For the Dominantly Inherited Alzheimer Network Trials

Mayo Clinic

Annals of Neurology | September 24, 2022 | Volume: 92 | Issue: 5 | Pages: 729-744

10.1002/ana.26511 | PMID 36151869 Get It

ObjectiveTo determine the characteristics of participants with amyloid‐related imaging abnormalities (ARIA) in a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease (DIAD).Methods142 DIAD mutation carriers received either gantenerumab SC (n = 52), solanezumab IV (n = 50), or placebo (n = 40). Participants underwent assessments with the Clinical Dementia Rating® (CDR®), neuropsychological testing, CSF biomarkers, β‐amyloid positron emission tomography (PET), and magnetic resonance imaging (MRI) to monitor ARIA. Cross‐sectional and longitudinal analyses evaluated potential ARIA‐related risk factors.ResultsEleven participants developed ARIA‐E, including 3 with mild symptoms. No ARIA‐E was reported under solanezumab while gantenerumab was associated with ARIA‐E compared to placebo (odds ratio [OR] = 9.1, confidence interval [CI][1.2, 412.3]; p = 0.021). Under gantenerumab, APOE‐ɛ4 carriers were more likely to develop ARIA‐E (OR = 5.0, CI[1.0, 30.4]; p = 0.055), as were individuals with microhemorrhage at baseline (OR = 13.7, CI[1.2, 163.2]; p = 0.039). No ARIA‐E was observed at the initial 225 mg/month gantenerumab dose, and most cases were observed at doses >675 mg. At first ARIA‐E occurrence, all ARIA‐E participants were amyloid‐PET+, 60% were CDR >0, 60% were past their estimated year to symptom onset, and 60% had also incident ARIA‐H. Most ARIA‐E radiologically resolved after dose adjustment and developing ARIA‐E did not significantly increase odds of trial discontinuation. ARIA‐E was more frequently observed in the occipital lobe (90%). ARIA‐E severity was associated with age at time of ARIA‐E.InterpretationIn DIAD, solanezumab was not associated with ARIA. Gantenerumab dose over 225 mg increased ARIA‐E risk, with additional risk for individuals APOE‐ɛ4(+) or with microhemorrhage. ARIA‐E was reversible on MRI in most cases, generally asymptomatic, without additional risk for trial discontinuation. ANN NEUROL 2022;92:729–744
Elevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia
Zhao, Na , Qiao, Wenhui , Li, Fuyao , Ren, Yingxue , Zheng, Jiaying , Martens, Yuka A. , Wang, Xusheng , Li, Ling , Liu, Chia‐Chen , Chen, Kai , Zhu, Yiyang , Ikezu, Tadafumi C. , Li, Zonghua , Meneses, Axel , Jin, Yunjung , Chen, Yixing , Sonustun, Berkiye , Job, Lucy , Smith, Madeleine L. , Xie, Manling , Liu, Yong , Umpierre, Anthony D. , Haruwaka, Koichiro , Quicksall, Zachary , Störz, Peter , Asmann, Yan W. , Wu, Long‐Jun , Bu, Guojun , Meneses, Axel D , Knight, Joshua A , Chen, Yixing , Bastea, Ligia , Linares, Cynthia , Sonustun, Berkiye , Job, Lucy , Smith, Madeleine L , Xie, Manling , Liu, Yong U , Umpierre, Anthony D , Haruwaka, Koichiro , Quicksall, Zachary S , Storz, Peter , Asmann, Yan W , Wu, Long-Jun , Bu, Guojun , Liu, Chia-Chen , Zhao, Na , Li, Fuyao , Zheng, Jiaying , Knight, Joshua A. , Bastea, Ligia I.

Mayo Clinic

Journal of Experimental Medicine | September 15, 2022 | Volume: 219 | Issue: 12 | Pages: No page available

10.1084/jem.20212479 | PMID 36107206 Get It

TREM2 is exclusively expressed by microglia in the brain and is strongly linked to the risk for Alzheimer’s disease (AD). As microglial responses modulated by TREM2 are central to AD pathogenesis, enhancing TREM2 signaling has been explored as an AD therapeutic strategy. However, the effective therapeutic window targeting TREM2 is unclear. Here, by using microglia-specific inducible mouse models overexpressing human wild-type TREM2 (TREM2-WT) or R47H risk variant (TREM2-R47H), we show that TREM2-WT expression reduces amyloid deposition and neuritic dystrophy only during the early amyloid seeding stage, whereas TREM2-R47H exacerbates amyloid burden during the middle amyloid rapid growth stage. Single-cell RNA sequencing reveals suppressed disease-associated microglia (DAM) signature and reduced DAM population upon TREM2-WT expression in the early stage, whereas upregulated antigen presentation pathway is detected with TREM2-R47H expression in the middle stage. Together, our findings highlight the dynamic effects of TREM2 in modulating AD pathogenesis and emphasize the beneficial effect of enhancing TREM2 function in the early stage of AD development.
Automated Cobb Angle Measurement in Adolescent Idiopathic Scoliosis: Validation of a Previously-Published Deep Learning Method
Shi, Yan , Ramazanian, Taghi , Yan, Shi, Constant, Caroline , Kremers, Hilal Maradit , Larson, A. Noelle

Mayo Clinic

2022 IEEE 10th International Conference on Healthcare Informatics (ICHI) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 495-496

10.1109/ichi54592.2022.00085 Get It

Deep Learning Method for Hip Knee Ankle Angle Prediction on Postoperative Full-Limb Radiographs of Total Knee Arthroplasty Patients
Yan, Shi , Ramazanian, Taghi , Chaudhary, Vipin , Kremers, Hilal Maradit

Mayo Clinic

2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 5070-5073

10.1109/embc48229.2022.9870936 | PMID 36086644 Get It

Abstract 6 Projected Impact of Omidubicel on Racial and Ethnic Disparities in Allogeneic Hematopoietic Cell Transplant Access and Outcomes for Patients with Hematologic Malignancies in the U.S.
Khera, Nandita , Edwards, Marie Louise, Song, Yan , Sun, Rochelle, Simantov, Ronit , Sivaraman, Smitha , Manghani, Rocio , Signorovitch, James , Gergis, Usama

Mayo Clinic

Stem Cells Translational Medicine | September 6, 2022 | Volume: 11 | Issue: Supplement_1 | Pages: S8-S8

10.1093/stcltm/szac057.006 Get It

Abstract Introduction Patients with hematologic malignancies (HM) who are eligible for allogeneic hematopoietic cell transplant (allo-HCT) often lack an HLA-matched related donor (MRD) and rely on unrelated donors for a matched or mismatched unrelated donor (MUD or MMUD) or on umbilical cord blood (UCB). It is well known that racial minorities are underrepresented in donor registries. Objective Omidubicel, an advanced cell therapy for allo-HCT, demonstrated superior hematopoietic recovery and clinical outcomes compared with standard UCB (NCT02730299). We hypothesized the impact of omidubicel access on racial and ethnic health disparities in a projection model. Methods A model was developed to project allo-HCT access and clinical outcomes in a hypothetical population of 10,000 allo-HCT-eligible US patients with HM lacking an HLA-MRD. Outcomes associated with omidubicel, MUD, MMUD, haploidentical or UCB HCT, or no transplant were assessed by race/ethnic group. Model inputs, including clinical outcomes for each HCT type, were drawn from clinical trials, public CIBMTR and US Department of Health and Human Services data, and published studies. Increasing omidubicel use was modeled, with proportional reductions in other allo-HCT types or no transplant. Results In a modeled population of 10,000 patients, 5,956 (60%) received allo-HCT utilizing current donor sources (MUD, MMUD, haploidentical, UCB) with no omidubicel (status quo). While 80% of white patients underwent allo-HCT, only 40% of Hispanic, 32% of Asian, and 22% of Black patients underwent allo-HCT. Mean time from selecting graft to HCT was 11.5 weeks. Including those not transplanted, 1-year OS was 62% overall, ranging from 56% (Black) to 65% (White). Modeled increases in omidubicel use in eligible patients were associated with higher proportions of patients undergoing allo-HCT, decreased time to HCT, and increased 1-year OS. Improvements were greatest among racial minorities. Assuming 20% omidubicel use, the proportion of patients receiving allo-HCT increased by 71% in Black, 43% in Asian, 30% in Hispanic, and 5% in White patients. Modeled time to allo-HCT improved as well. Discussion Access to omidubicel is projected to decrease time to allo-HCT, improve outcomes overall, with greatest improvements among racial and ethnic groups underserved by the status quo, thus helping to reduce racial disparities and improving health equity in allo-HCT.
IDDF2022-ABS-0084 Adar1-mediated RNA editing of scd1 links lipid metabolism to drug resistance and self-renewal in gastric cancer
Loh, Jia-Jian, Lu, Shi‐Xun, Yan, Helen HN, Siu, Hoi-Cheong, Chan, Dessy , Kam, Max JF, Copland, John A. , Chan, Leilei, Ren, Xi , Yun, Jing‐Ping , Leung, Suet-Yi, Wong, Tin Lok , Siu, Hoi Cheong , Zhou, Lei , Tong, Man , Leung, Suet-Yi

Mayo Clinic

Basic Gastroenterology | September 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: A45.1-A45

10.1136/gutjnl-2022-iddf.47 Get It

Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
Deng, Jing , Paulus, Aneel , Fang, Douglas D. , Manna, Alak , Wang, Guangfeng , Wang, Hengbang , Zhu, Saijie , Chen, Jianyong , Min, Ping , Yin, Yan , Dutta, Navnita , Halder, Nabanita , Ciccio, Gina , Copland, John A. , Miller, James L. , Han, Bing , Bai, Longchuan , Liu, Liu , Wang, Mi , McEachern, Donna , Przybranowski, Sally , Yang, Chao‐Yie , Stuckey, Jeanne A. , Li, Caixia , Letai, Anthony , Yang, Dajun , Wang, Shaomeng , Chanan‐Khan, Asher , Miller, James , Wu, Depei , Li, Caixia , Ryan, Jeremy , Letai, Anthony , Ailawadhi, Sikander , Yang, Dajun , Wang, Shaomeng , Chanan-Khan, Asher , Zhai, Yifan , Paulus, Aneel , Ryan, Jeremy , Ailawadhi, Sikander

Mayo Clinic

Clinical Cancer Research | September 1, 2022 | Volume: 28 | Issue: 24 | Pages: 5455-5468

10.1158/1078-0432.ccr-21-4037 | PMID 36048524 Get It

Abstract Purpose: Development of B-cell lymphoma 2 (BCL-2)–specific inhibitors poses unique challenges in drug design because of BCL-2 homology domain 3 (BH3) shared homology between BCL-2 family members and the shallow surface of their protein–protein interactions. We report herein discovery and extensive preclinical investigation of lisaftoclax (APG-2575). Experimental Design: Computational modeling was used to design “lead” compounds. Biochemical binding, mitochondrial BH3 profiling, and cell-based viability or apoptosis assays were used to determine the selectivity and potency of BCL-2 inhibitor lisaftoclax. The antitumor effects of lisaftoclax were also evaluated in several xenograft models. Results: Lisaftoclax selectively binds BCL-2 (Ki < 0.1 nmol/L), disrupts BCL-2:BIM complexes, and compromises mitochondrial outer membrane potential, culminating in BAX/BAK-dependent, caspase-mediated apoptosis. Lisaftoclax exerted strong antitumor activity in hematologic cancer cell lines and tumor cells from patients with chronic lymphocytic leukemia, multiple myeloma, or Waldenström macroglobulinemia. After lisaftoclax treatment, prodeath proteins BCL-2‒like protein 11 (BIM) and Noxa increased, and BIM translocated from cytosol to mitochondria. Consistent with these apoptotic activities, lisaftoclax entered malignant cells rapidly, reached plateau in 2 hours, and significantly downregulated mitochondrial respiratory function and ATP production. Furthermore, lisaftoclax inhibited tumor growth in xenograft models, correlating with caspase activation, poly (ADP-ribose) polymerase 1 cleavage, and pharmacokinetics of the compound. Lisaftoclax combined with rituximab or bendamustine/rituximab enhanced antitumor activity in vivo. Conclusions: These findings demonstrate that lisaftoclax is a novel, orally bioavailable BH3 mimetic BCL-2–selective inhibitor with considerable potential for the treatment of certain hematologic malignancies.